Establish Predictive CQAs Through Advanced Characterization & Heterogeneity Analysis

• Moving beyond particle size and reassessing CQAs for next-generation LNP therapeutics
• How should CQA strategies differ between discovery, IND-enabling, and commercial stages?
• How do we connect analytical attributes to potency, safety, and efficacy?

Speakers:

Zack Zhang

Senior Director, Analytical Research & Development,

Beam Therapeutics